Recent

% | $
Quotes you view appear here for quick access.

DepoMed Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tek_jansen500 tek_jansen500 Aug 2, 2011 11:22 AM Flag

    What happened on CC? Anything bad?

    Found the CC. Maybe some were put off by their statement about payers. Something along the lines of "We expect tier 3 or better coverage by many payers." I might have hoped for something more favorable than that.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • May not be profitable until 2013. Launch costs higher than expected, with large bills in 4th Q. I don't think these items came as a big suprise, but perhaps someone was expecting earlier profitability.

      • 2 Replies to acricketeer
      • I think Jim S has now clearly steered people to think of DEPO as preparing and executing a plan to become a regular commercial pharma company launching and selling drugs. Hence 2-year product launches with typical associated costs and modest revenue ramps. Jason, or Scott Henry’s question about the differences in contract sales forces required for Serada vs. Gralise really brought this home – not much synergy and would require different CSO forces. On the other hand, because DEPO was caught flat-footed with no viable way to sell Gralise when ABT formally reneged on the contract, they had no ability to execute another big-pharma partnership. Carl Pelzel clearly had me (and, I think, most investors) waiting for “the rapture” – partnerships with big pharmas that would shower money in increasing annual amounts upon DEPO. Well, that didn’t happen! Jim seems to have a much more pragmatic, workmanlike approach – that hopefully will also facilitate the sorely needed “big pharma” partnerships.

        But not too hard to see why an existing (or two) institutions would just decide to throw in the towel, though, which seems to have happened today. Carl had us all set up for an early dessert course.

        Though the P3 Breeze 3 results are a huge risk IMO, it still seems like there’s a decent shot of a variety of good news and cash positive events over the next 9 months. Today's valuation seems more than supported by existing drugs and development deals. Hunker down and hope for good top-line news from Serada in October. Sigh, being an investor sure sucks sometimes…still hoping for a pony…

      • Cric,

        Royalty from Merck should help DEPO break even for 2012.

    • tier 3 is better than no coverage or step therapy or prior authorization but still tier 3 could be bundled with the last two. It is a tough environment for extended release drug.

 
DEPO
18.88-0.79(-4.02%)Jun 24 4:00 PMEDT